---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-130480"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-03-30T23:59:59+00:00"
generated_at: "2026-05-15T08:23:08.129101+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tempest FY2025 net loss $26.3M; cash $7.7M; completed CAR-T acquisition

## Summary
- Net loss improved to $26.3M ($6.33/share) vs $41.8M ($19.50/share) in 2024.
- Cash at $7.7M at Dec 31, 2025, down from $30.3M at Dec 31, 2024.
- Completed all-stock acquisition of CAR-T assets from Factor Bioscience, including clinical-stage TPST-2003.
- TPST-2003 showed 100% CR in 6 evaluable rrMM patients; median PFS 23.1 months in prior IIT.
- Raised $2M upfront in March 2026 private placement with up to $4M additional from warrants.

## SEC filing metadata
- accession: 0001193125-26-130480
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-03-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/0001193125-26-130480-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/tpst-20260330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-130480
- JSON: https://secwatch.observer/filing/0001193125-26-130480.json
- Plain text: https://secwatch.observer/filing/0001193125-26-130480.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.